

Policy: MP203

Section: Medical Benefit Policy

Subject: Radiofrequency Ablation for Barrett's Esophagus

Applicable Lines of Business

Commercial	X	CHIP	X
Medicare	X	ACA	X
Medicaid	X		

I. Policy: Radiofrequency Ablation for Barrett's Esophagus

II. Purpose/Objective:

To provide a policy of coverage regarding Radiofrequency Ablation for Barrett's Esophagus

III. Responsibility:

- A. Medical Directors
- B. Medical Management

IV. Required Definitions

1. Attachment – a supporting document that is developed and maintained by the policy writer or department requiring/authoring the policy.
2. Exhibit – a supporting document developed and maintained in a department other than the department requiring/authoring the policy.
3. Devised – the date the policy was implemented.
4. Revised – the date of every revision to the policy, including typographical and grammatical changes.
5. Reviewed – the date documenting the annual review if the policy has no revisions necessary.

V. Additional Definitions

Medical Necessity or Medically Necessary means Covered Services rendered by a Health Care Provider that the Plan determines are:

- a. appropriate for the symptoms and diagnosis or treatment of the Member's condition, illness, disease or injury;
- b. provided for the diagnosis, and the direct care and treatment of the Member's condition, illness disease or injury;
- c. in accordance with current standards of good medical treatment practiced by the general medical community.
- d. not primarily for the convenience of the Member, or the Member's Health Care Provider; and
- e. the most appropriate source or level of service that can safely be provided to the Member. When applied to hospitalization, this further means that the Member requires acute care as an inpatient due to the nature of the services rendered or the Member's condition, and the Member cannot receive safe or adequate care as an outpatient.

Medicaid Business Segment

Medically Necessary — A service, item, procedure, or level of care that is necessary for the proper treatment or management of an illness, injury, or disability is one that:

- Will, or is reasonably expected to, prevent the onset of an illness, condition, injury or disability.
- Will, or is reasonably expected to, reduce or ameliorate the physical, mental or developmental effects of an

- illness, condition, injury or disability.
- Will assist the Member to achieve or maintain maximum functional capacity in performing daily activities, taking into account both the functional capacity of the Member and those functional capacities that are appropriate for Members of the same age.

DESCRIPTION:

The **Barrx System** consists of a high-powered radiofrequency energy generator and balloon. The balloon is entirely bipola and provides circumferential ablation to the esophagus to rapidly ablate the abnormal esophageal epithelium, while limiting thermal injury to the surrounding tissue. After approximately 1 month post-procedure, re-epithelialization begins, and abnormal cells are replaced with squamous epithelium.

INDICATIONS:

The Plan considers the use of the Barrx System medically necessary for those with documented evidence of Barrett's Esophagus with low-grade dysplasia.

Radiofrequency ablation as an alternative to esophagectomy is considered to be medically necessary when high-grade dysplasia in confirmed by endoscopy and life-expectancy is greater than one year.

EXCLUSIONS:

The Plan does **NOT** provide coverage for the Barrx System as a treatment for any other indication because it is considered **experimental, investigational or unproven**. Although the device is FDA approved, there is insufficient evidence in the peer-reviewed published medical literature to establish the effectiveness of this treatment on health outcomes when compared to established treatments or technologies

Note: A complete description of the process by which a given technology or service is evaluated and determined to be experimental, investigational or unproven is outlined in MP 15 - Experimental Investigational or Unproven Services or Treatment.

Medicaid Business Segment:

Any requests for services, that do not meet criteria set in the PARP, may be evaluated on a case by case basis.

CODING ASSOCIATED WITH: Radiofrequency Ablation for Barrett's Esophagus

The following codes are included below for informational purposes and may not be all inclusive. Inclusion of a procedure or device code(s) does not constitute or imply coverage nor does it imply or guarantee provider reimbursement. Coverage is determined by the member specific benefit plan document and any applicable laws regarding coverage of specific services. Please note that per Medicare coverage rules, only specific CPT/HCPCS Codes may be covered for the Medicare Business Segment. Please consult the CMS website at www.cms.gov or the local Medicare Administrative Carrier (MAC) for more information on Medicare coverage and coding requirements.

- 43229 Esophagoscopy, flexible, transoral; with ablation of tumor(s), polyp(s), or other lesion(s) (includes pre- and post-dilation and guide wire passage, when performed) [when specified as radiofrequency ablation]
- 43270 Esophagogastroduodenoscopy, flexible, transoral; with ablation of tumor(s), polyp(s) or other lesion(s) (includes pre- and post-dilation and guide wire passage, when performed) [when specified as radiofrequency ablation]

Current Procedural Terminology (CPT®) © American Medical Association: Chicago, IL

LINE OF BUSINESS:

Eligibility and contract specific benefits, limitations and/or exclusions will apply. Coverage statements found in the line of business specific benefit document will supersede this policy. For Medicare, applicable LCD's and NCD's will supercede this policy. For PA Medicaid Business segment, this policy applies as written.

REFERENCES:

Geisinger Technology Assessment Committee. Radiofrequency Ablation for Barrett's Esophagus (Barrx System). April 11, 2007.

Eisen GM. Ablation therapy for Barrett's esophagus. Gastrointest Endo 2003;58(5):760-769.

Hubbard N, Velanovich. Endoscopic endoluminal radiofrequency ablation of Barrett's esophagus in patients with funduplications. *Surg Endosc* 2007;21:625-628.

Winifred S. Hayes. Health Technology Brief (online). Barrxs HALO³⁶⁰Coagulation System (Barrx Medical Inc.) for Barrett's Esophagus. Winifred S Hayes. September 2006.

Sharma VK, Wang KK, Overholt BF, Lightdale CJ et al. Balloon-based, circumferential, endoscopic radiofrequency ablation of Barrett's esophagus: 1- year follow-up of 100 patients. *Gastrointest Endo* 2007;65(2):185-194.

Conio M, Cameron AJ, Chak A, Blanchi S, Filiberti R. Endoscopic Treatment of high-grade dysplasia and early cancer in Barrett's esophagus. *Lancet Oncol* 2005 May;6:311-321.

Ganz RA, Utley DS, Stern RA, Jackson J, Batts KP, Termin P. Complete ablation of esophageal epithelium with a balloon-based bipolar electrode: a phased evaluation in the porcine and in the human esophagus. *Gastrointest Endo* 2004;60(6):1002-1010.

Johnston MH, Technology insight: ablative techniques for Barrett's esophagus – current and emerging trends. *Nature Clinical Practice Gastroenter Hepat* 2005 July;2(7):323-330.

ECRI Institute. Custom Hotline Response (online). Balloon-based Radiofrequency ablation for Barrett's esophagus. ECRI Institute Current as of 07/20/06.

Ganz RA, Overholt BF, Sharma VK, et al. Circumferential ablation of barrett's esophagus that contains high-grade dysplasia: a U.S. multicenter registry. *Gastrointestinal Endoscopy* 2008;68(1):35-40.

Shaheen, N.J., Sharma, P., Overholt, B.F. et al. Radiofrequency ablation in Barrett's esophagus with dysplasia. *New England Journal of Medicine* 2009;360, 2277-88.

Frederik Hvid-Jensen, M.D., Lars Pedersen, Ph.D., et al. Incidence of Adenocarcinoma among Patients with Barrett's Esophagus *New England Journal of Medicine* 2011 October 13 ; 365:1375-1383

ECRI Institute. Emerging Technology Reports. Endoscopic radiofrequency ablation for Barrett's esophagus. ECRI Institute Current as of 12/28/2009.

UptoDate Radiofrequency ablation for Barrett's esophagus. last updated: May 24, 2018

Phoa KN, van Vilsteren FG, Weusten BL, et al. Radiofrequency ablation vs endoscopic surveillance for patients with Barrett esophagus and low-grade dysplasia: a randomized clinical trial. *JAMA*. 2014; 311(12):1209-1217.

Manner H, Rabenstein T, Pech O, et al. Ablation of residual Barrett's epithelium after endoscopic resection: a randomized long-term follow-up study of argon plasma coagulation vs. surveillance (APE study). *Endoscopy*. 2014; 46(1):6-12.

National Comprehensive Cancer Network. Esophageal and esophagogastric junction cancers. Version 1.2024

American Gastroenterological Association. Diagnosis and management of low-grade dysplasia in Barrett's esophagus: clinical practice updates expert review from the clinical guidelines committee of the American Gastroenterological Association. *Gastroenterology*, 2016 Oct 1

Standards of Practice Committee, Wani S, Qumseya B, et al. Endoscopic eradication therapy for patients with Barrett's esophagus-associated dysplasia and intramucosal cancer. *Gastrointest Endosc*. Apr 2018;87(4):907-931 e909.

Wani S, Qumseya B, Sultan S, et al. Endoscopic eradication therapy for patients with Barrett's esophagus-associated dysplasia and intramucosal cancer: American Society for Gastrointestinal Endoscopy, Standards of Practice Committee. *Gastrointest Endosc*. 2018; 87(4):907-931

Alves JR, Graffunder FP, Rech JVT, et al. Diagnosis, treatment and follow-up of Barrett's esophagus: a systematic review. *Arq Gastroenterol*. 2020; 57(3):289-295.

Fasullo M, Shah T, Patel M, et al. Outcomes of Radiofrequency Ablation Compared to Liquid Nitrogen Spray Cryotherapy for the Eradication of Dysplasia in Barrett's Esophagus. *Dig Dis Sci*. Jun 2022; 67(6): 2320-2326.

Agarwal S, Alshelleh M, Scott J, et al. Comparative outcomes of radiofrequency ablation and cryoballoon ablation in dysplastic Barrett's esophagus: a propensity score-matched cohort study. Gastrointest Endosc. Mar 2022; 95(3): 422-431.e2.

Shaheen NJ, Falk GW, Iyer PG, et al. Diagnosis and Management of Barrett's Esophagus: An Updated ACG Guideline. Am J Gastroenterol. Apr 01 2022; 117(4): 559-587.

This policy will be revised as necessary and reviewed no less than annually.

Devised: 06/2007

Revised: 5/15 (added indication)

Reviewed: 7/08, 7/09, 6/10, 6/11, 6/12, 6/13, 6/14, 6/16, 6/17, 5/18, 5/19, 5/20, 5/21, 5/22, 5/23, 5/24

CMS UM Oversight Committee Approval: 12/23

Geisinger Health Plan may refer collectively to health care coverage sponsors Geisinger Health Plan, Geisinger Quality Options, Inc., and Geisinger Indemnity Insurance Company, unless otherwise noted. Geisinger Health Plan is part of Geisinger, an integrated health care delivery and coverage organization.

Coverage for experimental or investigational treatments, services and procedures is specifically excluded under the member's certificate with Geisinger Health Plan. Unproven services outside of an approved clinical trial are also specifically excluded under the member's certificate with Geisinger Health Plan. This policy does not expand coverage to services or items specifically excluded from coverage in the member's certificate with Geisinger Health Plan. Additional information can be found in MP015 Experimental, Investigational or Unproven Services.

Prior authorization and/or pre-certification requirements for services or items may apply. Pre-certification lists may be found in the member's contract specific benefit document. Prior authorization requirements can be found at <https://www.geisinger.org/health-plan/providers/ghp-clinical-policies>

Please be advised that the use of the logos, service marks or names of Geisinger Health Plan, Geisinger Quality Options, Inc. and Geisinger Indemnity Insurance Company on a marketing, press releases or any communication piece regarding the contents of this medical policy is strictly prohibited without the prior written consent of Geisinger Health Plan. Additionally, the above medical policy does not confer any endorsement by Geisinger Health Plan, Geisinger Quality Options, Inc. and Geisinger Indemnity Insurance Company regarding the medical service, medical device or medical lab test described under this medical policy.